FE
FENC.US Fennec Pharmaceuticals Inc
- Market cap
- USD 410M
- P/E
- 387.3x
- P/B
- 9.01x
- ROE
- 18.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FENC.US undervalued?
Graham numberThe Graham number of Fennec Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fennec Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Fennec Pharmaceuticals Inc yet.
Fennec Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clini…
Full company profileFennec Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fennec Pharmaceuticals Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 170K | 170K | 1.54M | 21.3M | 47.5M | 44.6M | 70.1M |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | 170K | 0.00 | 1.45M | 20.0M | 44.4M | 40.9M | 67.3M |
| Operating Income | -2.87M | -6.95M | -10.4M | -13.0M | -17.9M | -17.2M | -22.7M | -13.1M | 2.48M | -6.35M | 8.36M |
| EBITDA | 116K | -348K | 1.03M | -12.9M | -17.7M | -17.2M | -22.6M | -12.4M | 4.80M | -7.45M | 9.33M |
| Net Income | -2.79M | -7.05M | -9.89M | -12.5M | -18.1M | -17.3M | -23.7M | -16.0M | -436K | -9.74M | 9.09M |
| EPS | -0.22 | -0.47 | -0.52 | -0.63 | -0.76 | -0.67 | -0.90 | -0.60 | -0.02 | -0.34 | 0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 3.97M | 28.4M | 23.0M | 14.1M | 31.4M | 22.4M | 26.9M | 26.9M | 44.9M | 70.1M | 83.5M |
| Total Liabilities | 402K | 1.64M | 1.64M | 2.27M | 2.35M | 6.64M | 29.5M | 38.5M | 50.8M | 35.0M | 34.4M |
| Shareholders' Equity | 3.57M | 26.8M | 21.3M | 11.9M | 29.1M | 15.8M | -2.57M | -11.6M | -5.87M | 35.1M | 49.2M |
| Cash & Short-term Investments | 3.93M | 28.3M | 22.8M | 13.7M | 30.3M | 21.1M | 23.8M | 13.3M | 26.6M | 36.7M | 48.7M |
| Total Debt | - | - | - | - | - | 5.00M | 24.9M | 31.0M | 19.3M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.12M | -3.64M | -7.83M | -9.06M | -15.6M | -14.2M | -18.1M | -17.1M | 27.0M | -12.5M | 12.1M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.75 | 0.00 | 0.00 | 1.33 |
| Free Cash Flow | -2.12M | -3.64M | -7.83M | -9.06M | -15.6M | -14.2M | -18.1M | -17.1M | 27.0M | -12.5M | 12.1M |
| Ratios | |||||||||||
| ROE | -78.1% | -26.3% | -46.4% | -104.9% | -62.3% | -110.0% | - | - | - | -27.8% | 18.5% |
| ROA | -70.2% | -24.8% | -43.1% | -88.1% | -57.6% | -77.4% | -88.0% | -59.7% | -1.0% | -13.9% | 10.9% |
| Net Profit Margin | - | - | - | - | -10,652.4% | -10,203.5% | -1,544.9% | -75.5% | -0.9% | -21.8% | 13.0% |
| Debt to Equity | - | - | - | - | - | 0.32x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fennec Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 529K | 0.02 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:3 on Sep 9, 2014.
Who owns Fennec Pharmaceuticals Inc
- Insiders 14.09%
- Institutions 57.26%
- Public & others 28.65%
- Shares outstanding 35.3M
- Free float 20.0M
Top funds holding FENC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 815K | 2.32% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 737K | 2.10% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 319K | 0.91% | +0.74% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 276K | 0.79% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 169K | 0.48% | +1.47% | Sep 2026 |
| Bridgeway Ultra-Small Company | 108K | 0.31% | +30.12% | Jun 2026 |
| CREF Total Global Stock Account R3 | 101K | 0.29% | +5.57% | Aug 2026 |
| iShares Micro-Cap ETF | 88.3K | 0.25% | 0.00% | Oct 2026 |
| 1290 Essex Small Cap Growth I | 81.4K | 0.23% | +1,308.46% | Sep 2026 |
| Lazard Baylight US Sm Cap Eq WW Dist EUR | 71.2K | 0.20% | 0.00% | Jul 2026 |
| Schwab Small Cap Index | 70.5K | 0.20% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 50.8K | 0.14% | +0.56% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 48.7K | 0.14% | -6.52% | Sep 2026 |
| SEI Small Cap II A (SIIT) | 42.2K | 0.12% | +4.53% | Oct 2026 |
| SEI Small Cap A (SIIT) | 35.6K | 0.10% | +8.58% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 33.8K | 0.10% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 Growth ETF | 32.0K | 0.09% | -0.01% | Sep 2026 |
| Fidelity Small Cap Growth Index | 28.8K | 0.08% | +0.54% | Aug 2026 |
| EQ/2000 Managed Volatility IB | 28.3K | 0.08% | 0.00% | Sep 2026 |
| SEI Small Cap F (SIMT) | 28.1K | 0.08% | 0.00% | Oct 2026 |
Top institutions holding FENC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3.19M | 9.09% | +9.62% | Jun 2026 |
| AIGH Capital Management, LLC | 2.49M | 7.09% | +25.46% | Jun 2026 |
| Solas Capital Management LLC | 1.89M | 5.39% | -23.88% | Jun 2026 |
| BlackRock Inc | 1.73M | 4.93% | +26.23% | Jun 2026 |
| Awm Investment Company Inc | 1.16M | 3.31% | +61.12% | Jun 2026 |
| Vanguard Capital Management, LLC | 839K | 2.39% | -6.45% | Jun 2026 |
| Prospect Capital Advisors, LLC | 498K | 1.42% | 0.00% | Jun 2026 |
| State Street Corp | 426K | 1.21% | +18.65% | Jun 2026 |
| Geode Capital Management, LLC | 403K | 1.15% | +8.29% | Jun 2026 |
| Jane Street Group LLC | 234K | 0.67% | 0.00% | Jun 2026 |
| Potomac Capital Management, Inc. | 224K | 0.64% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 222K | 0.63% | +5.12% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 200K | 0.57% | +18.71% | Jun 2026 |
| Northern Trust Corp | 168K | 0.48% | +10.39% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 139K | 0.40% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 134K | 0.38% | 0.00% | Jun 2026 |
| Nuveen, LLC | 131K | 0.37% | +115.73% | Jun 2026 |
| Sierra Summit Advisors LLC | 128K | 0.36% | 0.00% | Sep 2026 |
| Trexquant Investment LP | 119K | 0.34% | +129.66% | Jun 2026 |
| CenterBook Partners LP | 119K | 0.34% | 0.00% | Jun 2026 |
Fennec Pharmaceuticals Inc company profile
- Company name
- Fennec Pharmaceuticals Inc
- Ticker
- FENC.US
- ISIN
- CA31447P1009
- Exchange
- USA Stocks
- Listed since
- Jun 5, 2001
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Fiscal year end
- December
- Address
- 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
- Phone
- 919 636 4530
- Website
- fennecpharma.com
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc management
7- Mr. Jeffrey S. HackmanCEO & Director · born 1963
- Mr. Robert C. AndradeChief Financial Officer · born 1975
- Dr. Pierre S. Sayad M.S., Ph.D.Chief Medical Officer
- Mr. Terry EvansChief Commercial Officer
- Ms. Christiana Cioffi M.B.A.Chief Strategy Officer
- Mr. Mark GowlandController
- Mr. Lei FangPresident of Pharstat Inc